Fluoroquinolones linked to abnormal blood glucose levels.
TAIWAN -- Fluoroquinolones have been associated with higher rates of severe hyperglycemia (high blood glucose levels) and hypoglycemia (low blood glucose levels) than other classes of antibiotics in patients with diabetes. Among the fluoroquinolone class, moxifloxacin (Avelox[R]) carried the greatest risk.
Investigators used national health insurance claims from 2006 and 2007 from Taiwan to identify all patients with diabetes who received a new prescription for an oral fluoroquinolone, a second-generation cephalosporin, or a macrolide. Severe dysglycemia was defined as an episode of hyperglycemia or hypoglycemia resulting in a visit to the emergency department or hospitalization within 30 days after the start of antibiotic treatment. Fluoroquinolones, but not cephalosporins, showed a significantly increased risk of dysglycemia relative to macrolides, the reference drug category.
Gatifloxacin (Tequin[R]) was withdrawn from the market in 2006 because of its association with dysglycemia, and these antibiotics may cause hypoglycemia by increasing the body's release of insulin.
(Source: Clinical Infectious Diseases, August 15, 2013.)
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||MEDICAL NEWS FROM AROUND THE WORLD|
|Publication:||Nutrition Health Review|
|Date:||Jun 22, 2012|
|Previous Article:||Statins and death rates in patients with ventilator-associated pneumonia.|
|Next Article:||Effect of delaying prescriptions for antibiotics in patients with acute respiratory tract infections.|